Literature DB >> 14978240

Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.

Sayuri Oshikawa1, Akito Tanoue, Taka-aki Koshimizu, Yoko Kitagawa, Gozoh Tsujimoto.   

Abstract

Vasopressin receptor subtype(s) responsible for stimulation of insulin release from pancreatic beta cells were investigated by using subtype-selective antagonists and mice that were genetically lacking either V1a or V1b receptors. Arginine vasopressin (AVP) increased insulin release from isolated mouse islet cells in a concentration-dependent manner, with a submaximal response at 100 nM. Reverse transcription-polymerase chain reaction (RT-PCR) analysis detected V1b and oxytocin, but not V1a or V2, receptor transcripts in mouse islet cells. We characterized the recently synthesized vasopressin receptor subtype antagonists (2S)1-[(2R 3S)-(5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzene-sulfonyl)-3-hydroxy-2,3-difydro-1H-indole-2-carbonyl)-pyrrolidine-2-carboxamide] (SR49059), 1-[1-[4-(3-acetylaminopropoxy)benzoyl]-4-piperidyl]-3,4-dihydro-2(1H)-quinolinone (OPC-21268), and (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415) using human embryonic kidney 293 cells stably expressing the three cloned mouse vasopressin receptors (V1a, V1b, and V2). A radioligand binding study showed that SR49059 and OPC-21268 potently inhibited [3H]AVP binding to the cloned mouse V1a receptor, with Ki values of 27 and 510 nM, respectively, whereas SSR149415 potently inhibited [3H]AVP binding to the cloned mouse V1b receptor with a Ki value of 110 nM. The inhibitory effects of vasopressin antagonists on AVP-induced insulin release correlate well with the rank order of potency to inhibit [3H]AVP binding to the V1b receptor; pancreatic islet cells were significantly inhibited by SSR149415 but not by SR49059 or OPC-21268. Furthermore, the AVP effect on insulin release was entirely lost in mice lacking the V1b receptor but was preserved in mice lacking the V1a receptor. Our study, which combined pharmacological and knockout approaches, clearly demonstrates that vasopressin-stimulated insulin release from islet cells is mediated via V1b receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978240     DOI: 10.1124/mol.65.3.623

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  29 in total

1.  Insulin hypersensitivity in mice lacking the V1b vasopressin receptor.

Authors:  Yoko Fujiwara; Masami Hiroyama; Atsushi Sanbe; Toshinori Aoyagi; Jun-Ichi Birumachi; Junji Yamauchi; Gozoh Tsujimoto; Akito Tanoue
Journal:  J Physiol       Date:  2007-08-02       Impact factor: 5.182

2.  Impaired glucose tolerance, glucagon, and insulin responses in mice lacking the loop diuretic-sensitive Nkcc2a transporter.

Authors:  Lisa Kelly; Mohammed M Almutairi; Shams Kursan; Romario Pacheco; Eduardo Dias-Junior; Hayo Castrop; Mauricio Di Fulvio
Journal:  Am J Physiol Cell Physiol       Date:  2019-07-31       Impact factor: 4.249

Review 3.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

4.  Voluntary locomotion linked with cerebral activation is mediated by vasopressin V1a receptors in free-moving mice.

Authors:  Shizue Masuki; Eri Sumiyoshi; Taka-aki Koshimizu; Jinze Qian; Keiichi Higuchi; Gozoh Tsujimoto; Hiroshi Nose
Journal:  J Physiol       Date:  2013-05-13       Impact factor: 5.182

5.  Hyperammonaemia in V1a vasopressin receptor knockout mice caused by the promoted proteolysis and reduced intrahepatic blood volume.

Authors:  Masami Hiroyama; Toshinori Aoyagi; Yoko Fujiwara; Sayuri Oshikawa; Atsushi Sanbe; Fumio Endo; Akito Tanoue
Journal:  J Physiol       Date:  2007-03-22       Impact factor: 5.182

6.  Relationship between non-osmotic arginine vasopressin secretion and hemoglobin A1c levels in adult patients with congenital heart disease.

Authors:  Tomoaki Murakami; Yoko Horibata; Shigeru Tateno; Yasutaka Kawasoe; Koichiro Niwa
Journal:  Heart Vessels       Date:  2018-11-20       Impact factor: 2.037

7.  The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*.

Authors:  Marc O Maybauer; Dirk M Maybauer; Perenlei Enkhbaatar; Régent Laporte; Halina Wiśniewska; Lillian D Traber; ChiiDean Lin; Juanjuan Fan; Hal K Hawkins; Robert A Cox; Kazimierz Wiśniewski; Claudio D Schteingart; Donald W Landry; Pierre J-M Rivière; Daniel L Traber
Journal:  Crit Care Med       Date:  2014-07       Impact factor: 7.598

8.  A novel experimental strategy to assess the metabolic effects of selective activation of a G(q)-coupled receptor in hepatocytes in vivo.

Authors:  Jian Hua Li; Shalini Jain; Sara M McMillin; Yinghong Cui; Dinesh Gautam; Wataru Sakamoto; Huiyan Lu; William Jou; Owen P McGuinness; Oksana Gavrilova; Jürgen Wess
Journal:  Endocrinology       Date:  2013-07-16       Impact factor: 4.736

Review 9.  Arginine vasopressin receptor signaling and functional outcomes in heart failure.

Authors:  Melissa A Wasilewski; Valerie D Myers; Fabio A Recchia; Arthur M Feldman; Douglas G Tilley
Journal:  Cell Signal       Date:  2015-07-30       Impact factor: 4.315

10.  A complex selection signature at the human AVPR1B gene.

Authors:  Rachele Cagliani; Matteo Fumagalli; Uberto Pozzoli; Stefania Riva; Matteo Cereda; Giacomo P Comi; Linda Pattini; Nereo Bresolin; Manuela Sironi
Journal:  BMC Evol Biol       Date:  2009-06-01       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.